Want to see EXOZ full AI Analyst Report?
Top Page
eXoZymes
(NASDAQ:EXOZ)
Select Model
Select Model
Rating:44Neutral
Price Target:
$6.00
▼(-16.32% Downside)
Action:Reiterated
Date:09/09/26
The score is driven primarily by weak financial performance (no revenue, expanding losses, and ongoing cash burn), partially offset by acceptable current leverage and recent capital/grant funding. Technicals are mixed with a weak longer-term trend, and valuation is constrained by negative earnings and no dividend data. Corporate events add some support via NIH non-dilutive funding, but repeated offerings increase dilution risk.
Positive Factors
Moderate leverage
Debt has declined from about $1.24 million in 2025 to $0.74 million TTM, while debt-to-equity near 0.20 indicates leverage is not excessive relative to equity. This provides some financial flexibility as the company funds ongoing research and pipeline development.
Negative Factors
No revenue and widening losses
No reported revenue across the provided periods and widening net losses show that the business has not yet established commercial monetization. Persistent negative EBIT, EBITDA, and net income indicate substantial execution risk before the pipeline can produce recurring operating revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Moderate leverage
Debt has declined from about $1.24 million in 2025 to $0.74 million TTM, while debt-to-equity near 0.20 indicates leverage is not excessive relative to equity. This provides some financial flexibility as the company funds ongoing research and pipeline development.
Read all positive factors
eXoZymes (EXOZ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$57.45M
Dividend YieldN/A
Average Volume (3M)5.35K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue GrowthN/A
EPS Growth-21.64%
CountryUS
Employees32
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.20
Shares Outstanding9,281,359
10 Day Avg. Volume7,430
30 Day Avg. Volume5,346
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
eXoZymes Business Overview & Revenue Model
Company Description
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, ...
How the Company Makes Money
null...
eXoZymes Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 68.61K | 0.00 | -267.38K | 0.00 | -147.75K | -59.41K |
| EBITDA | -10.58M | -8.98M | -5.59M | -1.80M | -1.18M | -1.15M |
| Net Income | -10.19M | -9.16M | -5.86M | -2.04M | -1.40M | -1.21M |
Balance Sheet | ||||||
| Total Assets | 7.98M | 5.97M | 13.03M | 3.56M | 2.69M | 2.35M |
| Cash, Cash Equivalents and Short-Term Investments | 5.65M | 3.04M | 9.72M | 66.53K | 558.57K | 547.81K |
| Total Debt | 1.09M | 1.24M | 1.39M | 1.61M | 608.77K | 720.63K |
| Total Liabilities | 4.33M | 2.57M | 2.61M | 3.94M | 1.31M | 1.15M |
| Stockholders Equity | 3.65M | 3.40M | 10.42M | -384.32K | 1.37M | 1.20M |
Cash Flow | ||||||
| Free Cash Flow | -7.14M | -6.67M | -8.90M | -1.47M | -1.44M | -2.01M |
| Operating Cash Flow | -7.00M | -6.50M | -8.51M | -1.18M | -1.26M | -1.59M |
| Investing Cash Flow | -145.90K | -150.22K | -359.22K | -311.17K | -87.21K | -312.25K |
| Financing Cash Flow | 5.81M | -27.71K | 18.52M | 1.00M | 1.36M | 2.31M |
eXoZymes Technical Analysis
Neutral
7.17
Price Trends
6.00
Positive
7.45
Negative
8.87
Negative
Market Momentum
<0.01
Positive
50.62
Neutral
21.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EXOZ, the sentiment is Neutral. The current price of 7.17 is above the 20-day moving average (MA) of 6.69, above the 50-day MA of 6.00, and below the 200-day MA of 8.87, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.62 is Neutral, neither overbought nor oversold. The STOCH value of 21.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EXOZ.
eXoZymes Risk Analysis
eXoZymes disclosed 47 risk factors in its most recent earnings report. eXoZymes reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
eXoZymes Peers Comparison
UnderperformOutperform
Sector (55)
EXOZ
eXoZymes
6.44
-8.04
-55.53%
BDRX
Biodexa Pharmaceuticals
0.73
-32.32
-97.79%
ADTX
Aditxt
0.04
-23,675.72
-100.00%
NCEL
NewcelX
3.15
-17.25
-84.56%
VRAX
Virax Biolabs Group Ltd. Class A
2.54
-13.17
-83.83%
eXoZymes Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
eXoZymes Completes New Securities Offering to Fund Pipeline
Positive
Jul 1, 2026
On June 30, 2026, eXoZymes Inc. closed a registered securities offering of 35,555 units, each comprising one common share and one warrant, at $18.00 per unit, raising gross proceeds of about $640,000 and net proceeds after fees and expenses of rou...
Business Operations and StrategyPrivate Placements and Financing
eXoZymes Secures NIH Grant to Advance Cannabinoid Pipeline
Positive
Jun 26, 2026
On June 24, 2026, eXoZymes Inc. announced it had secured a $2.03 million Phase IIB Small Business Innovation Research grant from the National Institute of General Medical Sciences of the NIH to advance rare cannabinoid production and engineered ca...
Business Operations and StrategyPrivate Placements and Financing
eXoZymes Completes Nasdaq Equity Offering to Fund Pipeline
Positive
Jun 17, 2026
On June 17, 2026, Los Angeles-based eXoZymes Inc. announced the closing of an underwritten public offering of 330,575 units of common stock and warrants on Nasdaq, including 34,440 units issued through a partial exercise of the underwriters’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.